Tag: Delayed cerebral ischemia

Following an aneurysmal subarachnoid hemorrhage (aSAH), patients are at significant risk of delayed cerebral ischemia (DCI), a leading cause of severe disability and mortality. The standard of care to mitigate this risk involves a specific CCB: Nimodipine.

Subarachnoid hemorrhage (SAH) is a devastating type of stroke, with approximately 55% of patients being under the age of 55 when the event occurs. The primary pharmacological intervention used to manage this condition is nimodipine, answering the critical question: what is the drug of choice for subarachnoid hemorrhage? This calcium channel blocker is a cornerstone of treatment, aiming to improve neurological outcomes and prevent complications.

Aneurysmal subarachnoid hemorrhage (aSAH) is a devastating condition with a 1-month mortality rate of 10–40%. Effective pharmacological interventions are crucial, in addition to surgical or endovascular repair, to effectively treat aneurysmal subarachnoid hemorrhage and its cascade of secondary complications. These treatment strategies focus on stabilizing the patient, securing the ruptured aneurysm, and preventing or managing complications like delayed cerebral ischemia and hydrocephalus.